Report of first-stage accrual for NCI 5886, a phase II study of erlotinib, carboplatin and paclitaxel as first-line treatment of ovarian cancer Article

Blank, SV, Curtin, JP, Goldman, NA et al. (2006). Report of first-stage accrual for NCI 5886, a phase II study of erlotinib, carboplatin and paclitaxel as first-line treatment of ovarian cancer . JOURNAL OF CLINICAL ONCOLOGY, 24(18_suppl), 5076-5076. 10.1200/jco.2006.24.18_suppl.5076

cited authors

  • Blank, SV; Curtin, JP; Goldman, NA; Runowicz, CD; Speyer, JL; Tiersten, AD; Dancey, J; Wadler, S; Muggia, FM

authors

publication date

  • June 20, 2006

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 6 Evaluation of treatments and therapeutic interventions
  • 6.1 Pharmaceuticals
  • Cancer
  • Clinical Research
  • Orphan Drug
  • Ovarian Cancer
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • 5076

end page

  • 5076

volume

  • 24

issue

  • 18_suppl